Dry cough is the main clinical symptom of COVID-19 in the acute phase and often persists with the disease course. More importantly, coughing not only causes sore throat in the patient, but also promotes the spread of respiratory droplets and expands the scope of infection. Therefore, in the treatment of new crown , relieving cough symptoms is the top priority.
Since the outbreak of the epidemic, my country's Chinese patent medicines have been fighting on the road to fight the epidemic for three years and have achieved a lot of results. But even so, many people still have doubts: Are Chinese patent medicines really useful in the face of the new crown? Clinical review data shows that pure Western medicine symptomatic treatment and supportive treatment have limited effect on the treatment of new crown. Therefore, since the "Diagnosis and Treatment Plan" (2nd Edition), my country has included traditional Chinese medicine treatment in it, gradually improving and improving traditional Chinese medicine treatment plans in the clinical treatment process, and more traditional Chinese medicine varieties with accurate efficacy are included in it.
, a Chinese patent medicine Lianhua Qingke Tablet, guided by the theory of Chinese medicine network disease, and a combination of traditional classic prescriptions and clinical practice, is the first respiratory Chinese patent medicine approved during the COVID-19 epidemic. It has been successively entered into the new coronavirus pneumonia traditional Chinese medicine diagnosis and treatment plan by six provinces (cities) including Beijing, Shandong, Hubei, Hebei, Sichuan, Fujian. The effect of
Lianhua Qingke Tablets in the treatment of new coronary cough has been confirmed by clinical studies. A scientific paper entitled "Randomized controlled multicenter clinical study on the efficacy and safety of Lianhua Qingke Tablets in the treatment of mild and common COVID-19" published in the international academic journal "Evidence-Based Supplementary and Alternative Medicine" shows that compared with the control group, the clinical symptoms remission rate of Lianhua Qingke Tablets in the treatment of new coronary pneumonia increased by 14%, the median time for remission of cough and sputum was shortened by 3 days respectively, and the improvement rate of chest CT performance increased by 14%. Lianhua Qingcup Tablets can significantly improve the symptoms of coughing and sputum in patients with new coronary pneumonia, improve respiratory function, and reduce lung damage .
Lianhua Qingke Tablets targeted a series of pharmacological studies conducted by the new coronavirus in many domestic key laboratories and the drug safety evaluation center. The results confirmed that Lianhua Qingke Tablets can inhibit the replication of the new coronavirus in vitro and in vivo, reduce lung tissue inflammation, improve interstitial tissue hyperplasia, inhibit weight loss after infection, and regulate systemic immune function.
Coughing and sputum is the most common symptom of respiratory diseases. Nowadays, there are many guides for taking medications for COVID-19 on the Internet, and it is difficult to distinguish the authenticity. You may wish to directly refer to the consensus on diagnosis and treatment plans of the country or provinces and cities. Lianhua Qingke Tablets form a relatively complete chain of evidence for the new coronavirus pneumonia from multiple perspectives such as theory, practice, and evidence-based. Trustworthy. At present, the drug has been included in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog", becoming a new choice for clinicians to treat COVID-19 cough. Of course, after the general population develops symptoms such as coughing and fever, they should pay attention to protection and seek medical treatment in a timely manner.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-